About Theranexus

Company Description

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.

Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Year founded

2013

Served area

Worldwide

Headquarters

Pépinière Laennec 60 Avenue Rockefeller, 69008 Lyon – France

Shareholder information

Shares outstanding

4,083,849

IPO

Oct. 30, 2017

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.